MCID: SLP001
MIFTS: 50

Sleeping Sickness

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Sleeping Sickness

MalaCards integrated aliases for Sleeping Sickness:

Name: Sleeping Sickness 12 54 59 3 15
African Trypanosomiasis 12 76 59 3 73
African Sleeping Sickness 12
Trypanosomiasis, African 44
Trypanosomiasis African 55

Characteristics:

Orphanet epidemiological data:

59
african trypanosomiasis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:10112
ICD10 33 B56 B56.9
ICD9CM 35 086.5
MeSH 44 D014353
NCIt 50 C84541
SNOMED-CT 68 27031003 78940002
Orphanet 59 ORPHA3385
MESH via Orphanet 45 D014353
UMLS via Orphanet 74 C0041228
ICD10 via Orphanet 34 B56.0 B56.1 B56.9
UMLS 73 C0041228

Summaries for Sleeping Sickness

NINDS : 54 Encephalitis lethargica is a disease characterized by high fever, headache, double vision, delayed physical and mental response, and lethargy. In acute cases, patients may enter coma. Patients may also experience abnormal eye movements, upper body weakness, muscular pains, tremors, neck rigidity, and behavioral changes including psychosis. The cause of encephalitis lethargica is unknown. Between 1917 to 1928, an epidemic of encephalitis lethargica spread throughout the world, but no recurrence of the epidemic has since been reported. Postencephalitic Parkinson's disease may develop after a bout of encephalitis-sometimes as long as a year after the illness.

MalaCards based summary : Sleeping Sickness, also known as african trypanosomiasis, is related to chagas disease and leishmaniasis. An important gene associated with Sleeping Sickness is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are Metabolism and Vesicle-mediated transport. The drugs Ornithine and Nifurtimox have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and eye.

Disease Ontology : 12 A trypanosomiasis that results from infection by Trypanosoma brucei and gambiense, which is transmitted by the bite of an infected tsetse fly (Glossina spp). The symptoms include fever, headache, joint pain, itching, confusion, sensory disturbances, poor coordination and sleep disturbances.

CDC : 3 African Trypanosomiasis, also known as “sleeping sickness,” is caused by microscopic parasites of the species Trypanosoma brucei. It is transmitted by the tsetse fly (Glossina species), which is found only in rural Africa. Although the infection is not found in the United States, historically, it has been a serious public health problem in some regions of sub-Saharan Africa. Currently, about 10,000 new cases each year are reported to the World Health organization; however, it is believed that many cases go undiagnosed and unreported. Sleeping sickness is curable with medication, but is fatal if left untreated.

Wikipedia : 76 African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans... more...

Related Diseases for Sleeping Sickness

Diseases related to Sleeping Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 chagas disease 30.5 NOS2 IL6 IL10
2 leishmaniasis 30.1 SRM PGD NOS2 IL6 IL10
3 trypanosomiasis 30.1 TF ODC1 IL6 IL10 HPR HP
4 visceral leishmaniasis 29.7 PGD NOS2 IL10
5 malaria 29.5 TF SRM NOS2 IL6 IL10 HP
6 trypanosomiasis, human east-african 11.6
7 trypanosomiasis, human west-african 11.3
8 von economo's disease 11.2
9 eastern equine encephalitis 11.1
10 eye lymphoma 10.2 IL6 IL10
11 anhaptoglobinemia 10.2 HPR HP
12 rheumatic fever 10.1 IL6 IL10 HP
13 funisitis 10.1 IL6 IL10
14 idiopathic achalasia 10.1 NOS2 IL10
15 chlamydia 10.1 NOS2 IL6 IL10
16 gastroenteritis 10.1 MDH2 IL6 IL10
17 proteasome-associated autoinflammatory syndrome 1 10.1 NOS2 IL6 IL10
18 parasitic protozoa infectious disease 10.1 IL6 IL10 HP APOL1
19 acute transverse myelitis 10.1 IL6 IL10 APOA1
20 transverse myelitis 10.1 IL6 IL10 APOA1
21 thrombocytopenia 10.1
22 filariasis 10.1
23 filarial elephantiasis 10.1
24 schistosomiasis 10.1
25 baylisascariasis 10.1 IL10 GAPDH
26 nervous system disease 10.1 NOS2 IL6 IL10
27 encephalopathy 10.0
28 arteriosclerosis 10.0 IL6 IL10 APOA1
29 adult respiratory distress syndrome 9.9 TF IL6 IL10
30 cerebral artery occlusion 9.9 ODC1 NOS2
31 urinary system disease 9.9 TF IL6 APOL1
32 protein-energy malnutrition 9.9 TF IL6 HP
33 congenital disorder of glycosylation, type ia 9.9 TF HP ABCB7
34 atransferrinemia 9.9 TF HP ABCB7
35 glomerulonephritis 9.9
36 amblyopia 9.9
37 onchocerciasis 9.9
38 pseudobulbar palsy 9.9
39 endomyocardial fibrosis 9.9
40 uveitis 9.9
41 status epilepticus 9.9
42 orchitis 9.9
43 microsporidiosis 9.9
44 kidney disease 9.9
45 amebiasis 9.9
46 toxoplasmosis 9.9
47 hypoglycemia 9.9
48 anterior uveitis 9.9
49 splenomegaly 9.9
50 depression 9.9

Graphical network of the top 20 diseases related to Sleeping Sickness:



Diseases related to Sleeping Sickness

Symptoms & Phenotypes for Sleeping Sickness

Drugs & Therapeutics for Sleeping Sickness

Drugs for Sleeping Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ornithine Approved, Nutraceutical Phase 4,Phase 2,Phase 3 3184-13-2, 70-26-8 6262
2 Nifurtimox Investigational Phase 4,Phase 2,Phase 3 23256-30-6
3 Antiprotozoal Agents Phase 4,Phase 2,Phase 3
4 Antiparasitic Agents Phase 4,Phase 2,Phase 3
5 Anti-Infective Agents Phase 4,Phase 2,Phase 3
6 Melarsoprol Investigational Phase 3 494-79-1
7
Pentamidine Approved, Investigational Phase 2 100-33-4 4735
8
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
9
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
10
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
11
Pafuramidine Investigational Phase 2 186953-56-0
12
Maleic acid Experimental Phase 2 110-16-7 444266
13 Antifungal Agents Phase 2
14 Antioxidants Phase 2
15 Micronutrients Phase 2
16 Trace Elements Phase 2
17 Protective Agents Phase 2
18 Vitamins Phase 2
19
Caffeine Approved Not Applicable 58-08-2 2519
20
Dopamine Approved Not Applicable 51-61-6, 62-31-7 681
21
Methylphenidate Approved, Investigational Not Applicable 113-45-1 4158
22
Armodafinil Approved, Investigational Not Applicable 112111-43-0
23
Modafinil Approved, Investigational Not Applicable 68693-11-8 4236
24 Neurotransmitter Uptake Inhibitors Not Applicable
25 Purinergic P1 Receptor Antagonists Not Applicable
26 Wakefulness-Promoting Agents Not Applicable
27 Cytochrome P-450 CYP3A Inducers Not Applicable
28 Phosphodiesterase Inhibitors Not Applicable
29 Dopamine Uptake Inhibitors Not Applicable
30 Dopamine Agents Not Applicable
31 Neurotransmitter Agents Not Applicable
32 Central Nervous System Stimulants Not Applicable
33 Antibodies Not Applicable
34 Immunoglobulins Not Applicable

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase Completed NCT00906880 Phase 4 Nifurtimox-Eflronithine Combination Treatment (NECT)
2 Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study Unknown status NCT02184689 Phase 2, Phase 3 fexinidazole
3 Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study Unknown status NCT02169557 Phase 2, Phase 3 Fexinidazole
4 Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 Completed NCT01685827 Phase 2, Phase 3 Fexinidazole;Nifurtimox;Eflornithine
5 Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
6 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC Completed NCT01589289 Phase 3
7 Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Recruiting NCT03025789 Phase 3 Fexinidazole
8 Prospective Study on Efficacy and Safety of SCYX-7158 in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense Recruiting NCT03087955 Phase 2, Phase 3 SCYX 7158
9 Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda Terminated NCT00489658 Phase 2, Phase 3 Eflornithine plus Nifurtimox combination therapy
10 Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
11 Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00803933 Phase 2 DB289;Pentamidine
12 A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00802594 Phase 2 DB289
13 Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia Terminated NCT00184054 Phase 2 Arsenic Trioxide (ATO);Ascorbic Acid
14 Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole Completed NCT00982904 Phase 1 Fexinidazole/Placebo
15 Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158 Completed NCT01533961 Phase 1 SCYX-7158;Placebo
16 Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions Completed NCT01340157 Phase 1 Fexinidazole
17 Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food Terminated NCT01483170 Phase 1 Tablets Fexinidazole;Placebo
18 Effects of Modafinil, Caffeine and Methylphenidate in Healthy Volunteers Completed NCT02071615 Not Applicable Methylphenidate 20 mg tablet given once by mouth;modafinil 200mg tablet given once by mouth;caffein 200mg tablet given once by mouth;placebo
19 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) Completed NCT01766830 Not Applicable
20 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: Early Test-of-cure Recruiting NCT03112655 Not Applicable
21 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection Recruiting NCT03356665 Not Applicable
22 Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum Malaria Not yet recruiting NCT03394976

Search NIH Clinical Center for Sleeping Sickness

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: trypanosomiasis, african

Genetic Tests for Sleeping Sickness

Anatomical Context for Sleeping Sickness

MalaCards organs/tissues related to Sleeping Sickness:

41
Testes, Brain, Eye, T Cells, Heart, Lymph Node, Kidney

Publications for Sleeping Sickness

Articles related to Sleeping Sickness:

(show top 50) (show all 1495)
# Title Authors Year
1
Melarsoprol Resistance in African Trypanosomiasis. ( 29705579 )
2018
2
Integrated cost-benefit analysis of tsetse control and herd productivity to inform control programs for animal African trypanosomiasis. ( 29514668 )
2018
3
A case of delayed diagnosis of East-African trypanosomiasis in a Dutch traveller. ( 29688491 )
2018
4
An agent-based model of tsetse fly response to seasonal climatic drivers: Assessing the impact on sleeping sickness transmission rates. ( 29425200 )
2018
5
No evidence for association between APOL1 kidney disease risk alleles and Human African Trypanosomiasis in two Ugandan populations. ( 29470556 )
2018
6
Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo. ( 29897919 )
2018
7
Transcriptomes of Trypanosoma brucei rhodesiense from sleeping sickness patients, rodents and culture: Effects of strain, growth conditions and RNA preparation methods. ( 29474390 )
2018
8
African Trypanosomiasis-Associated Anemia: The Contribution of the Interplay between Parasites and the Mononuclear Phagocyte System. ( 29497418 )
2018
9
Brain-penetrant, triazolopyrimidine and phenylpyrimidine microtubule-stabilizers as potential leads to treat human African trypanosomiasis. ( 29969537 )
2018
10
FDG PET/CT in a Case of Human African Trypanosomiasis (Sleeping Sickness). ( 29863573 )
2018
11
Oral fexinidazole for human African trypanosomiasis. ( 29353603 )
2018
12
The impact of passive case detection on the transmission dynamics of gambiense Human African Trypanosomiasis. ( 29624584 )
2018
13
Assessing Strategies Against Gambiense Sleeping Sickness Through Mathematical Modeling. ( 29860287 )
2018
14
A Phase III Diagnostic Accuracy Study of a Rapid Diagnostic Test for Diagnosis of Second-Stage Human African Trypanosomiasis in the Democratic Republic of the Congo. ( 29246478 )
2018
15
Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT). ( 29169674 )
2018
16
Human African trypanosomiasis: How do the parasites enter and cause dysfunctions of the nervous system in murine models? ( 29870779 )
2018
17
Do Cryptic Reservoirs Threaten Gambiense-Sleeping Sickness Elimination? ( 29396200 )
2018
18
Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. ( 29191556 )
2018
19
Fluorine walk: The impact of fluorine in quinolone amides on their activity against African sleeping sickness. ( 29742443 )
2018
20
A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda. ( 29471865 )
2018
21
Human African Trypanosomiasis in Emigrant Returning to China from Gabon, 2017. ( 29350158 )
2018
22
Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. ( 29534061 )
2018
23
The development of high resolution maps of tsetse abundance to guide interventions against human African trypanosomiasis in northern Uganda. ( 29884213 )
2018
24
Sleeping sickness is a circadian disorder. ( 29302035 )
2018
25
Sleeping Sickness in the 'Omics Era. ( 29517161 )
2018
26
The structure of serum resistance-associated protein and its implications for human African trypanosomiasis. ( 29358741 )
2018
27
Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. ( 30453246 )
2018
28
In vitro antiprotozoal activity of some medicinal plants against sleeping sickness, Chagas disease and leishmaniasis. ( 30511591 )
2018
29
Prevalence of Sodalis glossinidius and different trypanosome species in Glossina palpalis palpalis caught in the Fontem sleeping sickness focus of the southern Cameroon. ( 30117802 )
2018
30
Description of the first sleeping sickness case diagnosed in Burkina Faso since two decades. ( 30125276 )
2018
31
Trypping up antigenic variation in sleeping sickness. ( 30389800 )
2018
32
Bacterial diversity obtained by culturable approaches in the gut of Glossina pallidipes population from a non sleeping sickness focus in Tanzania: preliminary results. ( 30470192 )
2018
33
Detection of Wolbachia and different trypanosome species in Glossina palpalis palpalis populations from three sleeping sickness foci of southern Cameroon. ( 30541614 )
2018
34
Integrating innovations: a qualitative analysis of referral non-completion among rapid diagnostic test-positive patients in Uganda's human African trypanosomiasis elimination programme. ( 30119700 )
2018
35
Clinical management of East African trypanosomiasis in South Africa: Lessons learned. ( 30153486 )
2018
36
The Long Wait for a New Drug for Human African Trypanosomiasis. ( 30181071 )
2018
37
Innovative digital technologies for quality assurance of diagnosis of human African trypanosomiasis. ( 30212459 )
2018
38
Cost-effectiveness of using a rapid diagnostic test to screen for human African trypanosomiasis in the Democratic Republic of the Congo. ( 30240406 )
2018
39
Knowledge, attitudes and practices about human African trypanosomiasis and their implications in designing intervention strategies for Yei county, South Sudan. ( 30273342 )
2018
40
Climate change and African trypanosomiasis vector populations in Zimbabwe's Zambezi Valley: A mathematical modelling study. ( 30346952 )
2018
41
Exploring the effect of human and animal population growth on vector-borne disease transmission with an agent-based model of Rhodesian human African trypanosomiasis in eastern province, Zambia. ( 30408045 )
2018
42
Human African trypanosomiasis caused by Trypanosoma brucei gambiense: The first case report in China. ( 30423460 )
2018
43
The elimination of human African trypanosomiasis is in sight: Report from the third WHO stakeholders meeting on elimination of gambiense human African trypanosomiasis. ( 30521522 )
2018
44
Monitoring the elimination of human African trypanosomiasis: Update to 2016. ( 30521525 )
2018
45
Relationship between Trypanosoma brucei rhodesiense genetic diversity and clinical spectrum among sleeping sickness patients in Uganda. ( 29078807 )
2017
46
Performance of the SD BIOLINEAr HAT rapid test in various diagnostic algorithms for gambiense human African trypanosomiasis in the Democratic Republic of the Congo. ( 28672036 )
2017
47
Human African trypanosomiasis control: Achievements and challenges. ( 28426685 )
2017
48
Case of Nigeria-Acquired Human African Trypanosomiasis in United Kingdom, 2016. ( 28628444 )
2017
49
Candidate gene polymorphisms study between human African trypanosomiasis clinical phenotypes in Guinea. ( 28827791 )
2017
50
Delineating neuroinflammation, parasite CNS invasion, and blood-brain barrier dysfunction in an experimental murine model of human African trypanosomiasis. ( 28636879 )
2017

Variations for Sleeping Sickness

Expression for Sleeping Sickness

Search GEO for disease gene expression data for Sleeping Sickness.

Pathways for Sleeping Sickness

Pathways related to Sleeping Sickness according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 ABCB7 AMD1 APOA1 CTPS1 GAPDH MDH2
2
Show member pathways
13.12 APOA1 APOL1 HP HPR HSPA8 TF
3 11.88 GAPDH IL10 IL6 TF
4
Show member pathways
11.76 AMD1 MDH2 SRM
5 11.68 HSPA8 IL10 IL6 NOS2
6 11.64 IL10 IL6 NOS2
7 11.59 MDH2 ODC1 SRM
8
Show member pathways
11.57 APOA1 APOL1 HP HPR
9 11.49 IL10 IL6 NOS2
10 11.46 GAPDH IL6 NOS2 TF
11 11.43 IL10 IL6 NOS2
12
Show member pathways
11.01 AMD1 NOS2 ODC1 SRM
13 10.79 APOA1 APOL1
14 10.57 APOA1 APOL1 HPR IL10 IL6

GO Terms for Sleeping Sickness

Cellular components related to Sleeping Sickness according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.86 APOA1 GAPDH HP HPR HSPA8 MDH2
2 perinuclear region of cytoplasm GO:0048471 9.85 GAPDH HSPA8 NOS2 ODC1 TF
3 endoplasmic reticulum lumen GO:0005788 9.62 APOA1 APOL1 IL6 TF
4 secretory granule lumen GO:0034774 9.58 APOA1 HSPA8 TF
5 extracellular space GO:0005615 9.56 APOA1 APOL1 HP HPR HSPA8 IL10
6 high-density lipoprotein particle GO:0034364 9.49 APOA1 APOL1
7 very-low-density lipoprotein particle GO:0034361 9.48 APOA1 APOL1
8 endocytic vesicle lumen GO:0071682 9.37 APOA1 HP
9 spherical high-density lipoprotein particle GO:0034366 9.16 APOA1 HPR
10 blood microparticle GO:0072562 9.1 APOA1 APOL1 HP HPR HSPA8 TF
11 extracellular region GO:0005576 10.03 APOA1 APOL1 HP HPR HSPA8 IL10

Biological processes related to Sleeping Sickness according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.8 APOA1 APOL1 IL6 TF
2 cytokine-mediated signaling pathway GO:0019221 9.76 HSPA8 IL10 IL6 NOS2
3 cellular protein metabolic process GO:0044267 9.67 APOA1 APOL1 IL6 TF
4 receptor-mediated endocytosis GO:0006898 9.62 APOA1 APOL1 HP HPR
5 response to organic substance GO:0010033 9.61 HP HPR IL10
6 acute inflammatory response GO:0002526 9.48 HP HPR
7 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.4 APOA1 IL10
8 negative regulation of cytokine secretion involved in immune response GO:0002740 9.26 APOA1 IL10
9 spermidine biosynthetic process GO:0008295 9.16 AMD1 SRM
10 polyamine biosynthetic process GO:0006596 9.13 AMD1 ODC1 SRM
11 polyamine metabolic process GO:0006595 8.8 AMD1 ODC1 SRM

Molecular functions related to Sleeping Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hemoglobin binding GO:0030492 8.96 HP HPR
2 NADP binding GO:0050661 8.8 GAPDH NOS2 PGD

Sources for Sleeping Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....